What topics does this cannabis study cover?

This study covers research on: THC, CBD, Mental Health, Endocannabinoid.

Where was this research published?

Published in British journal of clinical pharmacology on September 25, 2026.

Review distinguishes THC-related impairment from CBD’s non-intoxicating profile

Q: What did this research study find?

The *narrative review* proposes that **intoxication should be defined by functional impairment rather than psychoactivity alone**.

Cannabis-based medicines: On the topic of intoxication.

British journal of clinical pharmacology • September 25, 2026 • Highly Relevant

🤖

AI Summary

This narrative review examines what “intoxication” means for cannabis-based medicines and how it differs from related terms such as psychoactive, psychotropic, and euphorigenic. It synthesizes pharmacological, clinical, diagnostic, and regulatory literature rather than reporting a new clinical trial or a new participant sample. The review proposes that intoxication should be defined primarily by functional impairment, not by psychoactivity alone.

The review concludes that THC is a dose- and route-dependent intoxicant because it partially activates CB1 receptors. Oral use can increase exposure to the active metabolite 11-hydroxy-THC, which may raise the likelihood and severity of intoxication; individual patient factors also modify risk. In contrast, CBD is described as a negative allosteric modulator at CB1 and, at clinically relevant doses, as not producing euphoria or functional impairment and not meeting ICD-11 criteria for an intoxicant. As an abstract-based summary, this review cannot establish treatment benefits, provide quantitative estimates of risk, or replace assessment of the full underlying evidence.

💡 Key Findings

The narrative review proposes that intoxication should be defined by functional impairment rather than psychoactivity alone.

High

80%

THC is characterized as a dose- and route-dependent intoxicant through partial activation of CB1 receptors.

High

80%

Oral THC produces greater exposure to 11-hydroxy-THC, increasing the likelihood and severity of intoxication; patient-specific factors also modify risk.

Good

70%

At clinically relevant doses, CBD is reported to lack euphoria and functional impairment and not meet ICD-11 criteria for an intoxicant.

Good

70%

The review develops a taxonomy distinguishing psychoactive, psychotropic, euphorigenic, and intoxicant—but it does not provide new quantitative clinical outcomes.

High

80%

📄 Original Abstract

AIMS: This study aimed to clarify the pharmacological meaning of intoxication as it applies to cannabis-based medicines; distinguish intoxication from related terms such as psychoactive, psychotropic and euphorigenic; and evaluate how these distinctions inform clinical practice, prescribing frameworks and regulatory classification of THC- and CBD-containing products. METHODS: A narrative review of pharmacological, clinical and regulatory literature was conducted, drawing on cannabinoid receptor pharmacology, pharmacokinetic studies of THC and CBD, ICD-11 diagnostic criteria for substance intoxication, WHO scheduling assessments and international regulatory frameworks. Evidence was synthesised to develop a coherent clinical taxonomy and to examine the implications of dose, route of administration, patient-level modifiers and statutory definitions for classifying cannabinoids as intoxicants. RESULTS: THC is a partial CB1 receptor agonist and a dose- and route-dependent intoxicant. Oral administration produces substantially higher exposure to the active metabolite 11-hydroxy-THC, increasing intoxication likelihood and severity. Patient-specific factors further modify intoxication risk. CBD acts as a negative allosteric modulator at CB1, does not produce euphoria or functional impairment at clinically relevant doses and does not meet ICD-11 criteria for an intoxicant. A taxonomy distinguishing psychoactive, psychotropic, euphorigenic and intoxicant is proposed. CONCLUSION: THC and CBD differ fundamentally in receptor pharmacology, clinical effects and intoxication potential. Intoxication should be defined by functional impairment, not by psychoactivity alone. Adoption of precise, pharmacologically grounded terminology is essential for rational prescribing, informed consent, patient safety and coherent regulatory policy.